drugset / Trial / NCT01435460

Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

NCT01435460

Phase 3 Completed 300 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).

Timeline

Start
2010-08
Primary completion
2011-04
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Loteprednol Etabonate Other / unclassified 0.2 % Other
Comparator Olopatadine Other / unclassified 0.1 % Other

Indications